Skip to Main Content

Cryoglobulinemia can be associated with an immune-complex mediated, small-vessel vasculitis. Chronic infection with hepatitis C is the most common underlying condition; cryoglobulinemic vasculitis also can occur with other chronic infections (such as subacute bacterial endocarditis, osteomyelitis, HIV, and hepatitis B), with connective tissues diseases (especially Sjögren syndrome), and with lympho-proliferative disorders. The cryoglobulins associated with vasculitis are cold-precipitable immune complexes consisting of rheumatoid factor and IgG (rheumatoid factor is an autoantibody to the constant region of IgG). The rheumatoid factor component can be monoclonal (type II cryoglobulins) or polyclonal (type III cryoglobulins). (Type I cryoglobulins are cryoprecipitable monoclonal proteins that lack rheumatoid factor activity; these cause cold-induced hyperviscosity syndromes, not vasculitis, and are associated with B-cell lymphoproliferative diseases.)

CLINICAL FINDINGS

Cryoglobulinemic vasculitis typically manifests as recurrent palpable purpura (predominantly on the lower extremities) and peripheral neuropathy. A proliferative glomerulonephritis can develop and can manifest as rapidly progressive glomerulonephritis. Abnormal liver biochemical tests, abdominal pain, digital gangrene, and pulmonary disease may also occur. The diagnosis is based on a compatible clinical picture and a positive serum test for cryoglobulins. The presence of a disproportionately low C4 level can be a diagnostic clue to the presence of cryoglobulinemia.

TREATMENT

Antiviral regimens that do not include interferon are first-line therapy for hepatitis C–associated cryoglobulinemic vasculitis that is neither life- nor organ-threatening. Patients with severe cryoglobulinemic vasculitis (eg, extensive digital gangrene, extensive neuropathy, and rapidly progressive glomerulonephritis) and hepatitis C should receive immunosuppressive therapy with corticosteroids and either rituximab or cyclophosphamide as well as interferon-free antiviral therapy; plasma exchange may provide additional benefit in selected cases. Relapse of vasculitis with cryoglobulinemia following clearing of hepatitis C infection has been reported in a small percentage of patients.

+
Bonacci  MB  et al. Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure. Gastroenterology. 2018 Aug;155(2):311–5.
[PubMed: 29705529]  
+
Cacoub  P  et al. Cryoglobulinemia vasculitis. Am J Med. 2015 Sep;128(9):950–5.
[PubMed: 25837517]  
+
Desbois  AC  et al. Cryoglobulinemia vasculitis: how to handle. Curr Opin Rheumatol. 2017 Jul;29(4):343–7.
[PubMed: 28368978]  
+
Sise  ME  et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016 Feb;63(2):408–17.
[PubMed: 26474537]  

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.